Petros pharmaceuticals successfully completes important study in effort to make stendra(r) (avanafil) the first erectile dysfunction medication to achieve otc status

Human factor study represents important component of fda requirements for technology to pave way for stendra otc approval new york, ny / accesswire / december 12, 2023 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces the completion of a human factors study, whose objective was to assess the technology component developed to facilitate patient's access to its erectile dysfunction drug, stendra® (avanafil), associated with the company's intended fda application for prescription to otc switch. the objective of the study was to determine the strengths and weaknesses of the interface of a developmental technology tool, as well as potential use errors in critical tasks, such as navigating and reporting medical history, entering birth date and other key call to action prompts.
PTPI Ratings Summary
PTPI Quant Ranking